GNPTAB and prostate carcinoma: Further correlation analysis with clinicopathological markers for prostate cancer revealed a significant correlation of FZD5 expression and the PSA level (Figure 4H, r=0.01104, p=0.028) and between RYK-ICD and GS (Figure 4I, r=0.1468, p=0.003).